
Sign up to save your podcasts
Or


Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
By Wondery4.6
1254312,543 ratings
Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

10,446 Listeners

30,219 Listeners

775 Listeners

467 Listeners

3,993 Listeners

19,233 Listeners

4,164 Listeners

19,140 Listeners

2,151 Listeners

2,950 Listeners

3,044 Listeners

22,947 Listeners

904 Listeners

1,466 Listeners

7,771 Listeners

256 Listeners

2,507 Listeners

251 Listeners

2,152 Listeners

7,399 Listeners

851 Listeners

1,526 Listeners

237 Listeners

597 Listeners

429 Listeners

66 Listeners

535 Listeners

873 Listeners

209 Listeners